Working… Menu
Trial record 8 of 44 for:    TCR-T

EBV-TCR-T(YT-E001)for Patients With EBV-positive Recurrent or Metastatic NPC

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03648697
Recruitment Status : Recruiting
First Posted : August 27, 2018
Last Update Posted : August 11, 2020
China Immunotech (Beijing) Biotechnology Co., Ltd.
Information provided by (Responsible Party):
Fujian Cancer Hospital

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : October 8, 2021
Estimated Study Completion Date : October 10, 2021